Targeting ERAP1: Altering Neoantigen Presentation With a Small Molecule

Time: 1:00 pm
day: Day One

Details:

  • Tumor visibility, defined as the level of tumor-specific antigen expression, is shown to strongly correlate with response to checkpoint inhibition and is a vital aspect determining the immunogenicity within the tumor microenvironment
  • Grey Wolf have developed inhibitors of ERAP1, an aminopeptidase in the antigen presentation pathway that determines which antigens are presented on the surface of a cell or tumor
  • As opposed to developing a vaccine, Grey Wolf ERAP1 small molecule inhibitors alter the immunopeptidome and thus visibility of the tumor, triggering a differentiated T cell response and causing tumor growth inhibition

Speakers:

Peter Joyce